Byotrol PLC Directorate Change (3557V)
13 Dicembre 2021 - 8:00AM
UK Regulatory
TIDMBYOT
RNS Number : 3557V
Byotrol PLC
13 December 2021
Byotrol plc ("Byotrol" or the "Company")
Directorate Change
Byotrol plc (AIM: BYOT), the infection prevention technology
company, is pleased to announce the appointment of Chris Sedwell as
CFO of the Company. Chris joins the Board of Directors with
immediate effect.
Nic Hellyer, part-time CFO since May 2019 has now formally left
the Company, but will continue to be available to assist in an
orderly handover process.
Chris is ACA trained and an ICAEW fellow. He was most recently
Portfolio Finance Director of FD & CFO Centre, working with
various SMEs to provide finance consultancy. For the preceding six
years he was Finance Director of ConvaTec Limited, a FTSE250 listed
medical products and technologies business. Prior to this, he was
Head of Finance & Administration at Iceland International, a
part of the UK supermarket chain Iceland Foods Group.
At the date of this announcement, Mr Sedwell does not have any
beneficial interest in the ordinary shares of the Company.
Commenting on the appointment, John Langlands, Chairman of
Byotrol plc, said:
"We are very pleased to welcome Chris Sedwell to the Board of
Byotrol. He has a wealth of highly relevant industrial and
healthcare experience, from listed company to SME. We are convinced
that he will be a very important asset to the Company as we
continue to grow and develop.
We thank Nic Hellyer for his service to the Company and wish him
every success for the future."
Enquiries:
Byotrol Plc
John Langlands - Chairman
David Traynor - Chief Executive +44 (0)1925 742 000
finnCap (Nominated Adviser and Broker) +44 (0)20 7220 0500
Geoff Nash/Kate Bannatyne - Corporate
Finance
Richard Chambers - ECM
Flagstaff Strategic and Investor Communications +44 (0)20 7129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon byotrol@flagstaffcomms.com
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection
prevention and control company, operating globally in the
Healthcare, Industrial, Food and Consumer sectors, providing low
toxicity products with a broad-based and targeted efficacy across
all microbial classes; bacteria, viruses (including coronavirus),
fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients
within existing products, where they can significantly improve
their performance, especially in personal hygiene, domestic and
industrial disinfection, odour control, food production and food
management.
Byotrol develops and commercialises technologies that create
easier, safer and cleaner lives for everyone.
For more information, please go to byotrol.co.uk
Christopher John Sedwell, aged 45, is, or has been within the
last five years, a director or partner in the following companies
and partnerships:
Current directorships and partnerships Previous directorships and partnerships
held within the last five years
--------------------------------------- ----------------------------------------
S edwell Consulting Limited C onvaTec Limited
Unomedical Holdings Limited
C onvaTec Accessories Limited
Unomedical Limited
Amcare Limited
Alpha-Med (Medical & Surgical)
Limited
SureCalm Healthcare Limited
SureCalm Pharmacy Limited
Surecalm Healthcare Holdings
Limited
B.C.A Direct Limited
Resus Positive Limited
Akers & Dickinson Limited
Novacare UK Limited
Unomedical Developments Limited
Unoplast (UK) Limited
Steriseal Limited
Pharma-Plast Limited
Farnhurst Medical Limited
ConvaTec Speciality Fibres Limited
Nottingham Medical Equipment
Limited
Needle Industries (Sheffield)
Limited
Lance Blades Limited
M.S.B Limited
Rotax Razor Company Limited
Arthur Wood Limited
Allied Medical Services (UK)
Limited
Bradgate-Unitech Limited
Shrimpton & Fletcher Limited
--------------------------------------- ----------------------------------------
There are no further disclosures regarding Chris Sedwell
pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for
Companies.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAXAAFAAFFFA
(END) Dow Jones Newswires
December 13, 2021 02:00 ET (07:00 GMT)
Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Lug 2023 a Lug 2024